Cutting Edge Science to Create New Animal Health Pharmaceuticals

SMN-023 Drug candidate

Canine Atopic Dermatitis

  • Atopic dermatitis similar to eczema in humans, a life-long condition that can be difficult to manage
  • Affects approximately 10% of all dogs 

Dogs and their owners have many challenges 

  • Severe itching, hair loss, tearing of the skin, skin infection, flaky skin with foul odour 
  • Creates significant distress for pet owners requiring additional trips to the veterinarian and pharmaceutical interventions

SMN-023 First Drug Candidate for Maintenance Therapy

  Improve Canine Health:

  • Reducing the number of atopic dermatitis flares leads to healthier skin 
  • Healthier skin leads to reduced secondary bacterial infections

Improved Animal Welfare:

  • Reduce the stress and discomfort associated with atopic dermatitis flares

Reduce the Pet Owner Stress:

  • Fewer atopic dermatitis flares means fewer unscheduled vet visits and their inconvenience

Convenient Product Spray Format

  • Rather than daily pilling of your pet or monthly injections from your vet, two simple sprays a week may provide effective relief for your dog.

New Therapeutic Tool for Veterinarians

  • Offering veterinarians an option to help pet-owners achieve longer periods of relief and wellness for their dog.

Significant Data Supporting SMN-023 Development

  • Active ingredient - cyclosporine: demonstrated efficacy as an oral therapy for 15+ years in canine AD 
  • High skin penetration but no significant systemic exposure (expected to lead to improved safety profile)
  • Good skin safety profile 
  • Scalable & cGMP cost-effective production
  • Sprayable formulation and patent protected
  • No approved topical cyclosporine for either human or animal health

Clinical Development

The SMN-023 drug candidate has been de-risked across a number of important drug development dimensions including safety, efficacy, manufacturing, cost and intellectual property protection.


The next step in development is a dose confirmation study to advance SMN-023 to pivotal development.   The dose confirmation study is expected to commence in summer 2018.


Following a positive outcome from this study, Simini will advance SMN-023 to complete one pivotal efficacy and one pivotal safety study to support a New Animal Drug Application with the US Food and Drug Administration.

Volunteer for the Dose Confirmation Study

Do you have a dog that has atopic dermatitis?   We would like to hear from you and see if SMN-023 can provide improved outcomes for you and your dog while in clinical development.   


Send us an email at info@simini.com

About Us

Translating Human Health Research to Animal Health Products

  • 58 Billion US Dollars are spent annually in human health R&D
  • Less than 12% of human health drug candidates ultimately achieve product approval
  • Animal Drug approvals for new chemical entities remain less than 5 per year
  • Simini Technologies unites seasoned human and animal development professionals with one mission:
  • Mine the universe of innovation from human health to deliver new pharmaceuticals for our closest companions

Our Philosophy

We love technology.

Technology is both science and art.

The science is achieving maximum effect while providing the most convenient delivery.  

The art is developing optimal applications or combining effects to produce great solutions.

Our focus is the art of technology.

Translating cutting edge science from human health into new and effective pharmaceuticals for companion animals.


Our Approach

To exhaustively survey the latest scientific developments in human health for opportunities to advance breakthrough therapies that can change treatment paradigms in animal health.

Utilize a specialized team to evaluate each opportunity across multiple disciplines including: pharmacology, safety/toxicology, manufacturing, regulatory, intellectual property and marketing.

Work closely with in-licensing partners to create an arrangement of aligned interests that will be supportive for the development programs of our partners as well as animal health applications.

Interact collaboratively with regulatory agencies to insure development plans address the needs of patients, owners and veterinarians.  


Contact Us

Connect with Us

Simini Technologies

103 Sato Street, Whitby, Ontario, Canada L1R1V8

(647) 292-4920